Hormones and Cancer

  • M. G. Rowlands


Hormones are chemical ‘messengers’ that are synthesised in specialised body tissues called endocrine glands. In response to certain stimuli, hormones enter the circulation and are carried to their target tissues. In the target tissues, specific metabolic activities are stimulated or inhibited by the hormones, producing the required response to the original stimuli. On a structural basis, hormones fall into three categories, namely amino acid derivatives (thyroid hormones and catecholamines), peptide hormones [luteinising hormone (LH) and follicle-stimulating hormone (FSH)] and the steroid hormones (sex hormones and glucocorticoids). In addition, hormones differ in their mechanism of action. The steroids and thyroid hormones interact with their target tissues by entering the cells, whereas peptides and catecholamines act at the cell surface.


Breast Cancer Oestrogen Receptor Progesterone Receptor Endometrial Cancer Luteinising Hormone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    White, J.W. (1895) The results of double castration in hypertrophy of the prostate. Ann. Surg., 22, 1–6CrossRefGoogle Scholar
  2. 2.
    Beatson, G.T. (1896) On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet, ii, 104–7CrossRefGoogle Scholar
  3. 3.
    Jensen, E.V. & Jacobson, H.I. (1962) Basic guides to the mechanism of oestrogen action. Rec. Prog. Horm. Res., 18, 387–408Google Scholar
  4. 4.
    Folca, P.J., Glascock, R.F. & Irvine, W.T. (1961) Studies with tritium labelled hexoestrol in advanced breast cancer. Lancet, ii, 796–8CrossRefGoogle Scholar
  5. 5.
    King, R.J.B., Cowan, D.M. & Inman, D.R. (1965) The uptake of [3H]oestradiol by dimethylbenzanthracene induced rat mammary tumours. J. Endocrinol., 32, 83–90CrossRefGoogle Scholar
  6. 6.
    O’Malley, B.W. & Mears, A.R. (1974) Female steroid hormones and target nuclei. Science, 183, 610–20CrossRefGoogle Scholar
  7. 7.
    Katzenellenbogen, B.S., Miller, M.A., Eckert, R.L. & Sudo, K. (1983) Antioestrogen pharmacology and mechanism of action. J. Steroid Biochem., 19, 59–68CrossRefGoogle Scholar
  8. 8.
    Sledge, G.W. & McGuire, W.L. (1983) Steroid hormone receptors in human breast cancer. Adv. Cancer Res., 38, 61–75CrossRefGoogle Scholar
  9. 9.
    Huggins, C., Stevens, R.E., Jr & Hodges, C.V. (1941) Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch. Surg., 43, 209–14CrossRefGoogle Scholar
  10. 10.
    Haddow, A., Watkinson, J.M., & Patterson, E. (1944) Influence of synthetic oestrogens upon advanced malignant disease. Br. Med. J., ii, 393–8CrossRefGoogle Scholar
  11. 11.
    McGuire, W.L., Pearson, O.H. & Segaloff, A. (1975) Predicting hormone responsiveness in human breast cancer. In W.L. McGuire, P.P. Carbone, E.P. Vollmer (eds) Estrogen Receptors in Human Breast Cancer, Raven Press, New York, pp. 17–29Google Scholar
  12. 12.
    Thompson, E.A., Jr & Siiteri, P.K. (1974) The involvement of human placental microsomal cytochrome P450 in aromatization. J. Biol. Chem., 249, 5373–8Google Scholar
  13. 13.
    Santen, R.J., Badder, E., Lerman, S., Harvey, H., Lipton, A., Boucher, A.E., Manni, A., Rosen, H. & Wells, S.A. (1982) Pharmacologic suppression of oestrogens with aminoglutethimide as treatment of advanced breast carcinoma. Breast Cancer Res. Treat., 2, 375–83CrossRefGoogle Scholar
  14. 14.
    Santen, R.J. & Misbin, R.I. (1981) Aminoglutethimide: review of pharmacology and clinical use. Pharmacotherapy, 1, 95–117Google Scholar
  15. 15.
    Jordan, V.C. (1982) Metabolites of tamoxifen in animals and man: identification, pharmacology and significance. Breast Cancer Res. Treat., 2, 123–38CrossRefGoogle Scholar
  16. 16.
    Patterson, J.S. (1981) Clinical aspects and development of antioestrogen therapy: review of the endocrine effects of tamoxifen in animals and man. J. Endocrinol, 89, 67P–75PGoogle Scholar
  17. 17.
    Murray, R. & Pitt, P. (1983) Inhibition of adrenal steroid synthesis with aminoglute-thimide in advanced prostatic cancer. J. Steroid Biochem., 19, 11sCrossRefGoogle Scholar
  18. 18.
    Kelley, R.M. & Baker, W.H. (1961) Progestational agents in the treatment of carcinoma of the endometrium. N. Engl. J. Med., 264, 216–22CrossRefGoogle Scholar
  19. 19.
    Kohorn, E.I. (1976) Oestrogens and endometrial carcinoma. Gynecol. Oncol., 4, 398–411CrossRefGoogle Scholar
  20. 20.
    Vihko, R., Isotalo, H., Kuappila, A. & Vierikko, P. (1983) Female sex steroid receptors in gynaecological malignancies: clinical correlates. J. Steroid Biochem., 19, 827–32CrossRefGoogle Scholar
  21. 21.
    Kirkman, H. & Bacon, R.L. (1950) Malignant renal tumours in male hamsters treated with oestrogens. Cancer Res., 10, 122–4Google Scholar
  22. 22.
    Bloom, H.J.G. (1973) Hormone-induced and spontaneous regression of metastatic renal cancer. Cancer, 32, 1066–71CrossRefGoogle Scholar
  23. 23.
    Greenway, B., Iqbal, M.J, Johnson, P.J. & Williams, R. (1981) Oestrogen receptor proteins in malignant and fetal pancreas. Br. Med. J., 283, 751–3CrossRefGoogle Scholar
  24. 24.
    Iqbal, M.J., Greenway, B., Wilkinson, M.L., Johnson, P.J. & Williams, R. (1983) Sex-steroid enzymes, aromatase and 5a-reductase in the pancreas: a comparison of normal adult, foetal and malignant tissue. Clin. Sci., 65, 71–5Google Scholar
  25. 25.
    Bell, P.A. (1979) Assessment of the glucocorticoid responsiveness of human leukaemias and lymphomas. In B.A. Stoll (ed.) Reviews on Endocrine-related Cancer, vol. 4, ICI Pharmaceuticals, UK, pp. 5–12Google Scholar
  26. 26.
    Brodie, A.M.H., Garrett, W.M., Hendrickson, J.R. , Tsai-Morris, C.H. & Williams, J.G. (1983) Aromatase inhibitors: their pharmacology and application. J. Steroid Biochem., 19, 53–8CrossRefGoogle Scholar
  27. 27.
    Neumann, F. & Jacobi, G.H. (1982) Antiandrogens in tumour therapy. In B.J.A. Furr (ed.) Clinics in Oncology, vol. 1, W.B. Saunders, Philadelphia, pp. 41–64Google Scholar
  28. 28.
    Coombes, R.C., Perez, D., Gazet, J.-C., Ford, H.-T. & Powles, T.J. (1983) Danazol treatment for advanced breast cancer. Cancer Chemother. Pharmacol., 10, 194–5Google Scholar
  29. 29.
    Nicholson, R.I. & Walker, K.J. (1983) Control of hormone dependent cancers of the breast and prostate by the LH-RH agonist ICI 118630. J. Steroid Biochem., 19, 83sCrossRefGoogle Scholar
  30. 30.
    Allen, J.M, O’Shea, J.P., Mashito, K., Williams, G. & Bloom, S.R. (1983) Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing hormone agonist. Br. Med. J., 286, 1607–9CrossRefGoogle Scholar
  31. 31.
    Borgmann, W., Hardt, W., Schmidt-Gollwitzer, M., Adenauer, H. & Nagel, R. (1982) Sustained suppression of testosterone production by the luteinising-hormone agonist, buserelin in patients with advanced prostate carcinoma. Lancet, i, 1097–9CrossRefGoogle Scholar
  32. 32.
    Powles, T.J., Gordon, C., Coombes, R.C. (1982) Clinical trial of multiple endocrine therapy for metastatic and locally advanced breast cancer with tamoxifen-aminoglute-thimide-danazol compared to tamoxifen used alone. Cancer Res., 42, (Suppl.) 3458s–60sGoogle Scholar

Further Reading

  1. Furr, B.J.A. (ed.) Hormone therapy. Clinics in Oncology, vol. 1, W.B. Saunders, PhiladelphiaGoogle Scholar
  2. Jensen, E.V. (1981) Hormone therapy. In S.T. Crooke & A.W. Prestayko (eds) Cancer and Chemotherapy, vol. 3, Academic Press, New York, pp. 187–204Google Scholar
  3. Stoll, B.A. (1981) Hormonal Management of Endocrine Related Cancer, Lloyd-Luke (Medical Books), LondonGoogle Scholar

Copyright information

© Peter B. Farmer and John M. Walker 1985

Authors and Affiliations

  • M. G. Rowlands

There are no affiliations available

Personalised recommendations